会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 28. 发明授权
    • Method of bonding to gold surface and resultant combinations
    • 粘合到金表面和结合组合的方法
    • US08323800B2
    • 2012-12-04
    • US12481291
    • 2009-06-09
    • Daniel HainesDavid YuhasEric Urruti
    • Daniel HainesDavid YuhasEric Urruti
    • B32B15/08B32B17/06B32B37/02
    • C03C27/048C09J5/06C09J2400/123C09J2400/143C09J2400/163Y10T428/31612Y10T428/31678
    • The present invention relates to a method of bonding a gold surface to a second surface which comprises heating a hybrid organic-inorganic melting gel >50° C., applying the melting gel to either the gold surface or the second surface. The melting gel is heated to above 130° C. until the melting gel has cured sufficiently to bond the surfaces together. The invention also relates to a combination of a gold surface and a second surface that is bonded together with a hybrid organic-inorganic melting gel. In another aspect of the invention the hybrid organic-inorganic melting gel is heated to a workable viscosity and cast into a film, sheet, block or lens. The cast gel is cured or partially cured and then applied between the gold surface and the second surface. Additional uncured melting gel may be applied. The construct is heated to above 130° C. until the melting gel has cured sufficient to bond the surfaces together.
    • 本发明涉及一种将金表面粘合到第二表面上的方法,其包括加热> 50℃的杂化有机 - 无机熔融凝胶,将熔融凝胶施加到金表面或第二表面上。 将熔融的凝胶加热至130℃以上,直到熔融的凝胶充分固化以将表面粘合在一起。 本发明还涉及金表面和与混合有机 - 无机熔融凝胶结合在一起的第二表面的组合。 在本发明的另一方面,将混合有机 - 无机熔融凝胶加热至可行的粘度并浇铸成膜,片,块或透镜。 浇铸凝胶固化或部分固化,然后施加在金表面和第二表面之间。 可以应用另外的未固化的熔融凝胶。 将构造体加热至130℃以上,直到熔融凝胶固化足以将表面粘合在一起。
    • 29. 发明授权
    • Process of mild hydrocracking including a dilution of the feedstock
    • 轻度加氢裂化的方法,包括原料稀释
    • US07718050B2
    • 2010-05-18
    • US11449867
    • 2006-06-09
    • Christophe GueretThierry ChapusDamien Hudebine
    • Christophe GueretThierry ChapusDamien Hudebine
    • C10G57/00B01J8/18
    • C10G69/04C10G11/18C10G47/00
    • The invention relates to a process for FCC pretreatment by mild hydrocracking of a hydrocarbon feedstock that comprises a vacuum distillate fraction or a deasphalted oil or else a mixture of these two fractions, said primary feedstock, to produce gas oil and an effluent having an initial boiling point of more than 320° C., said effluent (FCC feedstock) then being subjected to a catalytic cracking, process in which at least 85% by weight of said primary feedstock ends above 375° C. and at least 95% by weight of said primary feedstock ends below 650° C., whereby the mild hydrocracking is performed under an absolute pressure of 2 to 12 MPa and at a temperature of between 300 and 500° C., characterized in that the hydrocarbon feedstock also comprises a lighter hydrocarbon fraction, a so-called secondary feedstock, of which at least 50% by weight ends below 375° C. and at least 80% ends above 200° C.
    • 本发明涉及通过烃原料的轻度加氢裂化来进行FCC预处理的方法,所述烃原料包括真空蒸馏馏分或脱沥青油,或者所述主要原料的这两个馏分的混合物,以产生瓦斯油和具有初始沸点的流出物 所述流出物(FCC原料)然后进行催化裂化,其中至少85重量%的所述主要原料在375℃以上终止,并且至少95重量% 所述主要原料终止于650℃以下,由此在2至12MPa的绝对压力和300至500℃的温度下进行轻度加氢裂化,其特征在于,烃原料还包含较轻的烃馏分 ,所谓的二次原料,其中至少50重量%终止于375℃以下且至少80%在200℃以上结束。
    • 30. 发明授权
    • VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
    • VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶
    • US07615565B2
    • 2009-11-10
    • US11525091
    • 2006-09-22
    • Andreas HuthLudwig ZornMartin KrugerStuat InceKarl-Heinz ThierauchAndreas MenradMartin HabereyHolger Hess-Stumpp
    • Andreas HuthLudwig ZornMartin KrugerStuat InceKarl-Heinz ThierauchAndreas MenradMartin HabereyHolger Hess-Stumpp
    • A61K31/47C07D217/22
    • C07D213/72C07D401/02
    • VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.
    • 描述了VEGFR-2和VEGFR-3抑制性邻氨基苯酰胺吡啶酰胺,其作为用于治疗由持续血管发生引起的疾病的药物的制备和用途,以及用于制备化合物的中间产物。 根据本发明的化合物可用于或在肿瘤或转移生长的情况下,牛皮癣,卡波西肉瘤,再狭窄,例如支架诱导的再狭窄,子宫内膜异位,克罗恩病,霍奇金病,白血病; 关节炎,如类风湿关节炎,血管瘤,血管纤维瘤; 眼睛疾病如糖尿病性视网膜病变,新生血管性青光眼; 肾脏疾病如肾小球性肾炎,糖尿病肾病,恶性肾硬化,血栓性微血管病综合征,移植排斥反应和肾小球病; 纤维化疾病,如肝硬化,肾小球膜细胞增生性疾病,动脉硬化,神经组织损伤,以及球囊导管治疗后血管再狭窄的抑制,血管修复术或机械装置用于保持血管开放的诸如 例如作为免疫抑制剂的支架,作为无疤痕愈合的支持,老年角化病和接触性皮炎。 在淋巴管生成的情况下,根据本发明的化合物也可以用作VEGFR-3抑制剂。